Results 41 to 50 of about 238,930 (305)

Dendritic cell maturation assay for non-clinical immunogenicity risk assessment: best practices recommended by the European Immunogenicity Platform

Frontiers in Immunology
Early assessment and mitigation of non-clinical immunogenicity risk during early drug development is key for the development of safe and efficacious therapeutics.
Chloé Ackaert, Bruno Gonzalez-Nolasco, Marc Rosenbaum, Mercedes Perez-Olivares, Michael Gutknecht, Axel Ducret, Anette Christine Karle   +6 more
doaj   +1 more source

Stimulator of interferon genes agonist augmented antitumor immunity of osimertinib in Egfr‐mutated lung cancer

Molecular Oncology, EarlyView.
Combining osimertinib with the STING agonist ADU‐S100 activates innate and adaptive immunity to overcome the non‐inflamed microenvironment of Egfr‐mutant lung cancer. This combination increases NK and CD8+ T‐cell infiltration, associated with activation of the STING‐IRF3 pathway and local immunogenic cell death.
Jun Nishimura, Tadahiro Kuribayashi, Johannes Brägelmann, Sachi Okawa, Masataka Taoka, Shunta Mori, Tomoka Nishimura, Takaaki Tanaka, Go Makimoto, Kiichiro Ninomiya, Kammei Rai, Eiki Ichihara, Ryohei Katayama, Katsuyuki Hotta, Masahiro Tabata, Yosuke Togashi, Yoshinobu Maeda, Martin L. Sos, Katsuyuki Kiura, Kadoaki Ohashi   +19 more
wiley   +1 more source

Complex immunogenicity assessment in caplacizumab-treated patients with immune-mediated thrombotic thrombocytopenic purpura who have received plasma exchange

Research and Practice in Thrombosis and Haemostasis
Background: International Society on Thrombosis and Haemostasis guidelines for immune-mediated thrombotic thrombocytopenic purpura (iTTP) treatment recommend concurrent therapeutic plasma exchange (TPE), immunosuppressive therapy (IST), and caplacizumab.
Brendy Van Butsel, Maria Laura Sargentini-Maier, Ana Paula Marques, Yana Vandenbossche, Gabriela Marcheva, Sriya Gunawardena, Samuel Pine   +6 more
doaj   +1 more source

A dermatologist guide to immunogenicity

International Journal of Women's Dermatology, 2016
Dermatologists should be aware that autoantibody formation may occur after the initiation of biologic therapy. This phenomenon has been referred to as immunogenicity and biologic fatigue. Because of this, patients may experience loss of clinical efficacy to a particular drug.
Collin M. Blattner, DO, Soham P. Chaudhari, DO, John Young, III, MD, Jenny E. Murase, MD   +3 more
openaire   +3 more sources

Tumor B‐cell infiltration in platinum‐treated advanced muscle‐invasive urothelial carcinoma

Molecular Oncology, EarlyView.
Bladder tumors with higher pretreatment memory B‐cell infiltration were linked to longer survival after cisplatin chemotherapy, but not carboplatin. These tumors also showed more organized immune structures (tertiary lymphoid structures) and a shared pro‐inflammatory B‐cell‐rich community, suggesting that memory B cells may help identify patients most ...
Konrad Stawiski, Júlia Perera‐Bel, Alejo Rodriguez‐Vida, Nuria Juanpere, Jihyun Lee, Daniel E. Michaud, Jennifer L. Guerriero, Kent W. Mouw, Aristotelis Bamias, Filipe L. F. Carvalho, Joaquim Bellmunt   +10 more
wiley   +1 more source

MAPPs assays for non-clinical immunogenicity risk assessment: best practices recommended by the European immunogenicity platform

Frontiers in Immunology
The use of the MAPPs (Major histocompatibility complex Associated Peptide Proteomics) assay by pharmaceutical companies, service providers, and academic laboratories is rapidly increasing, attesting to its increasingly pivotal role in biotherapeutic drug
A.C. Karle, K. L. Kopp, R.J. Seward, S. Tourdot, C. Ackaert, M. Gutknecht, E. Cloake, N. Smith, A. Ducret   +8 more
doaj   +1 more source

Satisfactory safety and immunogenicity of MSP3 malaria vaccine candidate in Tanzanian children aged 12-24 months. [PDF]

, 2009
BACKGROUND: Development and deployment of an effective malaria vaccine would complement existing malaria control measures. A blood stage malaria vaccine candidate, Merozoite Surface Protein-3 (MSP3), produced as a long synthetic peptide, has been shown ...
Gesase Samwel, Druilhe, Pierre, Chilengi Roma, Roma Chilengi, Method D Segeja, Seth, Misago, Msham Salum, Francis Filbert, Lemnge, Martha, Samwel Sembuche, Salum Msham, Noor Ramadhani, Cousens Simon, Sembuche, Samwel, Minja Daniel, Martha Lemnge, Simon Cousens, Samuel Bosomprah, Chilengi, Roma, Samwel Gesase, Lusingu, John PA, Gesase, Samwel, John PA Lusingu, Rutta, Acleus, Bosomprah Samuel, Cousens, Simon, Ramadhani Noor, Acleus Rutta, Pierre Druilhe, Seth Misago, Segeja Method D, Minja, Daniel, Msham, Salum, Druilhe Pierre, Daniel Minja, Francis, Filbert, Noor, Ramadhani, Lemnge Martha, Bosomprah, Samuel, Lusingu John PA, Rutta Acleus, Misago Seth, Segeja, Method D, Sembuche Samwel, Filbert Francis   +44 more
core   +1 more source

Rapid screening of staphylokinase protein variants using an unpurified cell‐free expression system

FEBS Open Bio, EarlyView.
An unpurified cell‐free protein synthesis (CFPS) platform enables rapid functional screening of staphylokinase variants. Direct plasminogen‐activation assays performed in microplate format provide real‐time activity readouts, allowing rapid identification and ranking of variants with improved or reduced fibrinolytic activity without protein ...
Maria Tomková, Veronika Hovanová, Jiri Damborsky, Erik Sedlák   +3 more
wiley   +1 more source

Taking immunogenicity assessment of therapeutic proteins to the next level

, 2011
Therapeutic proteins provide innovative and effective therapies for numerous diseases. However, some of these products are associated with unwanted immunogenicity that may lead to clinical consequences such as reduced or loss of efficacy, altered ...
Mire-Sluis, A, Subramanyam, M., T. Platts-Mills, Stas, P., Krause, R, Reipert, BM, R. Krause, Trouvin, JH, J. Windisch, Jefferis, R., D. Kramer, Schellekens, H., Thorpe, R, F. Ehmann, Lubiniecki, A., Buttel, I.C., P. Chamberlain, Sub Biotechnological drugs, Platts-Mills, T, Kramer, D, R. Seitz, Weise, M., Stas, P, Ragheb, J.A., Chowers, Y, P. Stas, Windisch, J., Kramer, D., Schneider, CK, Greinacher, A., Lloyd, P, A. Greinacher, Windisch, J, J.A. Ragheb, Ehmann, F., Seitz, R., R. Jefferis, Reipert, B.M., A. Mire-Sluis, Pharmaceutics, H. Schellekens, M. Weise, Buettel, IC, Chowers, Y., C.K. Schneider, Ragheb, JA, Greinacher, A, Kropshofer, H, M. Subramanyam, Schneider, C.K., Lubiniecki, A, Mire-Sluis, A., J.-H. Trouvin, H. Kropshofer, Innovation Studies, R. Thorpe, Kropshofer, H., Lloyd, P., Seitz, R, Ehmann, F, P. Lloyd, Subramanyam, M, Weise, M, Y. Chowers, Jefferis, Royston, Thorpe, R., A. Lubiniecki, Chamberlain, P., Krause, R., I.C. Büttel, Trouvin, J.H., B.M. Reipert, Platts-Mills, T., Chamberlain, P, Schellekens, H   +74 more
core   +1 more source

Derivation and characterization of retinal pigment epithelium from urine‐derived iPSCs

FEBS Open Bio, EarlyView.
Age‐related macular degeneration causes vision loss via RPE dysfunction and loss. Traditional iPSC therapies rely on invasive biopsies, limiting scalability. Here, we utilize urine‐derived stem cells as an accessible source to generate u‐iPSCs, successfully differentiated into pigmented RPE. This “Urine‐to‐Retina” platform provides a promising path for
Daniella Beiner, Hainan Zhu, Carol Christine Bosholm, Heuy‐Ching Wang, Tracy Criswell, Anthony Atala, Jian‐Xing Ma, Yuanyuan Zhang   +7 more
wiley   +1 more source